This is a preview of subscription content, log in via an institution to check access.
Notes
2013 euros
2013 euros
Reference
Corro Ramos I, et al. Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines. Value in Health : 20 Jun 2017. Available from: URL: https://doi.org/10.1016/j.jval.2017.05.013
Rights and permissions
About this article
Cite this article
Sacubitril/valsartan cost effective for HF in Netherlands. PharmacoEcon Outcomes News 781, 32 (2017). https://doi.org/10.1007/s40274-017-4124-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4124-3